VOLITIONRX LTD — Director's Dealing 2020

Jan 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2020-01-12

Reporting Person: TERRELL JASON BRADLEY MD (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-12	Common Stock	D	11364	$4.79	Disposed	50000	Direct

Footnotes

F1: The reported transaction, consisting of the Issuer's repurchase of shares of common stock from the Reporting Person, was approved by the compensation committee of the Board of Directors (comprised of three "non-employee directors") and, pursuant to Rule 16b-3(e), is exempted from matching for purposes of Section 16(b) of the Exchange Act.